Elevai Labs, Inc. Common Stock (NASDAQ:ELAB) — Market Cap & Net Worth
Market Cap & Net Worth: Elevai Labs, Inc. Common Stock (ELAB)
Elevai Labs, Inc. Common Stock (NASDAQ:ELAB) has a market capitalization of $2.77 Million ($2.77 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29594 globally and #5963 in its home market, demonstrating a 1.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elevai Labs, Inc. Common Stock's stock price $1.43 by its total outstanding shares 1936771 (1.94 Million). Review Elevai Labs, Inc. Common Stock balance sheet liabilities to assess the company's total debt and financial obligations.
Elevai Labs, Inc. Common Stock Market Cap History: 2023 to 2026
Elevai Labs, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows change from $708.08 Million to $2.77 Million (-90.89% CAGR).
Index Memberships
Elevai Labs, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2777 of 3165 |
Weight: Elevai Labs, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elevai Labs, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elevai Labs, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.86x
Elevai Labs, Inc. Common Stock's market cap is 4.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $708.08 Million | $1.71 Million | -$4.30 Million | 413.46x | N/A |
| 2024 | $4.44 Million | $2.47 Million | -$6.25 Million | 1.80x | N/A |
| 2025 | $2.87 Million | $590.08K | -$7.71 Million | 4.86x | N/A |
Competitor Companies of ELAB by Market Capitalization
Companies near Elevai Labs, Inc. Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to Elevai Labs, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Elevai Labs, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Elevai Labs, Inc. Common Stock's market cap moved from $708.08 Million to $ 2.77 Million, with a yearly change of -90.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.77 Million | -3.38% |
| 2025 | $2.87 Million | -35.37% |
| 2024 | $4.44 Million | -99.37% |
| 2023 | $708.08 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Elevai Labs, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.77 Million USD |
| MoneyControl | $2.77 Million USD |
| MarketWatch | $2.77 Million USD |
| marketcap.company | $2.77 Million USD |
| Reuters | $2.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the med… Read more